WO2004020614A1 - 異形断面中空糸膜型細胞含有デバイス - Google Patents
異形断面中空糸膜型細胞含有デバイス Download PDFInfo
- Publication number
- WO2004020614A1 WO2004020614A1 PCT/JP2003/010952 JP0310952W WO2004020614A1 WO 2004020614 A1 WO2004020614 A1 WO 2004020614A1 JP 0310952 W JP0310952 W JP 0310952W WO 2004020614 A1 WO2004020614 A1 WO 2004020614A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hollow fiber
- cell
- fiber membrane
- section
- containing device
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
Definitions
- organ-like aggregates such as spherical aggregates (spheroids) and cylindrical aggregates (cylindroids) has recently been established. It is now possible to realize the high functionality of and maintain its long-term function.
- PU F polyurethane foam
- spheroids spherical aggregates
- Japanese Patent Laid-Open No. Hei 10 Japanese Patent Laid-Open No. Hei 10
- 2 9 95 1, H. I j ima et al. “Tissue Engineering” 4th, 2nd, pp. 213-226 (1 998)
- PU F is a porous material with a main skeleton and a thin membrane beam structure, and the PU F pores communicate with each other to some extent, so that high-density culture can be achieved in a good material exchange environment.
- hepatocytes When hepatocytes are cultured in the PU F pore, about 200 hepatocytes gradually gather and spontaneously form many spherical aggregates (spheroids) with a particle size of about 1 O Oim.
- the present inventors have already succeeded in developing a human clinical scale short-term application type (about 10 cm) bioartificial liver using a spherical aggregate (spheroid) using this culture method.
- these conventional cell aggregates are limited to a spherical shape (spheroid) or a cylindrical shape (cylindroid) using a perfect circular hollow fiber membrane.
- the hollow fiber membrane type is easy to handle and functional as a device.
- oxygen and nutrients do not reach the central cells sufficiently, resulting in necrosis.
- the filled cells cannot be used efficiently without waste. There was a problem.
- This cell utilization efficiency is particularly problematic when the cell source for producing cell aggregates (organoides) is extremely difficult to obtain, such as from brain-dead donors.
- the hollow fiber membrane has an inner diameter that is too small, it may be difficult to produce a uniform hollow fiber membrane and modularize it, and it may easily cause air locks, etc., affecting the uniform filling operation of cells.
- a hollow fiber membrane type cell culture device is known, and a cell for culturing cells inside the hollow fiber membrane and supplying a culture solution to the outside, It is roughly divided into the opposite type.
- Sho 62-1717 1678 discloses that cells are cultured inside or outside a deformed hollow fiber membrane having fins extending in the longitudinal direction at the outer periphery.
- Japanese Patent Application Laid-Open No. Sho 6 3-2 3 3 7 7 7 discloses culturing cells outside a hollow fiber membrane having hollows with irregularities.
- the hollow fiber membrane may be an ellipse instead of a perfect circle
- it is a hollow fiber membrane that requires fins (fin-shaped convex portions) outside the membrane. Therefore, the main purpose was to prevent the membranes from sticking to each other and improve the dispersibility of the culture medium and cells.
- the inside of the membrane is uneven in the longitudinal direction, thereby causing turbulence in the culture medium flowing inside the membrane and trying to prevent clogging of the membrane.
- the present invention relates to a hollow fiber membrane type cell-containing device in which cells are filled into the hollow fiber to form a cell aggregate, and the filled cell can be efficiently used without waste, and the variant that can improve the cell utilization efficiency It is an object of the present invention to provide a cross-section hollow fiber membrane type cell-containing device. Another object of the present invention is to provide an artificial organ using such a modified cross-section hollow fiber membrane type cell-containing device. Furthermore, another object of the present invention is to provide a method for manufacturing the device or artificial organ.
- a cell aggregate formed by filling a deformed cross-section hollow fiber membrane with a target cell and having a specific size forms a necrotic layer in the filled cell.
- the present invention was completed by discovering that cell functions can be exhibited efficiently without any problems.
- the present inventors have 1) not the conventional circular hollow fiber membrane, but the cell and the inner wall of the hollow fiber membrane. If the deformed cross-section hollow fiber membrane is used while maintaining the distance at which the cells are not necrotized, the inner diameter of the hollow fiber membrane is not limited at all, 2) It came to the mind that if it is manufactured by deforming it, it becomes possible to use commercially available hollow fiber membranes that are known for various materials and permeation performance.
- Such a modified cross-section hollow fiber membrane cell-containing device can be freely designed for cell-membrane affinity and substance permeability, and as a result, can be applied from implantable to circulating hybrid artificial organs. I came up with a much wider range. There has been no report on cell aggregates (organoids) using such a modified cross-section hollow fiber membrane.
- the present invention relates to the following (1) to (29).
- the hollow fiber membrane has an irregular cross section, and the cell aggregate formed in the hollow part has an arbitrary direction. Two or more layers of cells are laminated on each other, and the distance from an arbitrary point of the cell aggregate to the nearest inner wall of the hollow fiber membrane is less than 75 m.
- thermoplastic resin is a polyethylene resin.
- the animal tissue-derived cell is at least one cell selected from the group consisting of a liver-derived cell, a spleen-derived cell, and their stem cells, progenitor cells, or genetically modified cells.
- the deformed cross-section hollow fiber membrane type cell-containing device according to any one of the above (10) to (12), wherein the animal tissue-derived cell is a human organ-derived cell.
- a cell-containing device comprising a hollow fiber membrane and a cell, comprising a cell aggregate in a hollow part, wherein both ends of the hollow fiber membrane are sealed. Any of the cross-section hollow fiber membrane cell-containing devices for implantation described in any one of the above.
- a hybrid artificial organ comprising at least one modified cross-section hollow fiber membrane cell-containing device described in any one of (1) to (13) above.
- At least one deformed cross-section hollow fiber membrane type cell-containing device described in any one of (1) to (13) is accommodated in a container having an inlet and an outlet for the liquid to be treated.
- a hybrid artificial organ characterized in that the hollow inside of the hollow fiber membrane-type cell-containing device is isolated from the inside and outside of the air that forms the flow path of the liquid to be treated.
- a method for producing a modified cross-section hollow fiber membrane cell-containing device comprising at least the following steps.
- the animal tissue-derived cell is at least one cell selected from the group consisting of a liver-derived cell, a spleen-derived cell, and their stem cells, progenitor cells, or genetically modified cells.
- a method for producing a hybrid artificial organ comprising the method for producing a cell-containing device according to any one of (18) to (27).
- a method for producing a hybrid artificial organ characterized in that a cell aggregate is formed.
- the cells filled in the deformed cross-section hollow fiber membrane function efficiently without waste without forming a necrotic layer, and thus function efficiently as a hybrid artificial organ.
- FIG. 1 is a schematic view showing a cross section of a modified cross-section hollow fiber membrane of the present invention.
- FIG. 2 is a schematic view showing a method for producing a modified cross-section hollow fiber membrane of the present invention.
- FIG. 3 is a photomicrograph showing a cross section of the modified cross-section hollow fiber membrane of the present invention.
- FIG. 4 is an electron micrograph showing the surface of the PE Z E V AL irregular cross-section hollow fiber membrane of the present invention.
- FIG. 5 is an electron micrograph showing the surface of the PP modified cross-section hollow fiber membrane of the present invention.
- FIG. 6 is a photomicrograph showing a cross section of the modified cross-section hollow fiber membrane type cell-containing device of the present invention (culture day 3, HE staining).
- FIG. 7 is a graph showing the change over time of the cell maintenance rate by the modified cross-section hollow fiber membrane type cell-containing device of the present invention.
- FIG. 8 is a graph showing the ammonia removal rate by the modified cross-section hollow fiber membrane cell-containing device of the present invention.
- FIG. 9 is a graph showing the albumin secretion rate by the modified cross-section hollow fiber membrane type cell-containing device of the present invention.
- FIG. 10 is a photomicrograph showing the influence of surface hydrophilization on the formation of cell aggregates (organoide) in the modified cross-section hollow fiber membrane of the present invention (1 hour culture).
- FIG. 11 is a photomicrograph showing the effect of surface hydrophilization on cell adhesion in the modified cross-section hollow fiber membrane of the present invention (culture day 1).
- FIG. 12 is a schematic diagram showing the hybrid artificial organ of the present invention.
- FIG. 13 is a schematic view showing a state in which cells are filled and fixed in a built-in deformed cross-section hollow fiber membrane in the hybrid artificial organ of the present invention.
- the modified cross-section hollow fiber membrane of the present invention is not intended to have a cross-sectional structure in which both the inner and outer circumferences usually used for blood purification membranes and ultrafiltration membranes are round and concentric, but at least the hollow fiber membrane.
- Intentionally deformed inner cross-sectional structure especially deformed so that the distance from any point of the cell aggregate (organoide) formed in the hollow part to the nearest inner wall of the hollow fiber membrane falls within a specific range It has been made.
- specific shapes include flat and elliptical shapes, as well as polygons such as triangles, quadrilaterals, and pentagons, as well as irregular shapes including stagnation and star shapes. In view of ease of filling and handling of the membrane, a flat shape or an elliptical shape is preferable, and a flat shape is particularly preferable.
- the modified cross-section hollow fiber membranes are preferably substantially equal in concentric shape (in other words, the film thickness is substantially uniform) from the viewpoint of material permeability and uniformity of strength, Depending on the purpose, the inner and outer circumferences may have different shapes.
- the irregular cross section referred to in the present invention indicates a cross section when the hollow fiber membrane is cut substantially perpendicularly to the fiber axis direction.
- Japanese Patent Laid-Open No. 6-3 2 3 3 7 7 The shape that is irregular in the fiber axis direction described in No. 7 is also out of the category. Such a shape does not achieve the purpose of keeping the distance between the cell of the present invention and the inner wall of the hollow fiber membrane at a distance that does not necrotize the cell, and it is difficult to manufacture uniformly and to fill the cell. is there.
- the modified cross-section hollow fiber membrane may be any known hollow fiber membrane structure such as a sponge structure, a uniform structure, a macro-void structure, etc. as the structure of the film thickness portion. However, it may be crimped in a wavy manner.
- the material of the modified cross-section hollow fiber membrane used in the present invention is preferably a thermoplastic resin from the viewpoint of deformation processing described later.
- a thermoplastic resin for example, polyolefin-based, polyester-based, polysulfone-based, polyethersulfone-based, polypropylene-based, polyethylene And polyacrylonitrile, polymethyl methacrylate, polyvinyl chloride, and polyamide resins.
- These materials are called “ ⁇ ⁇ ⁇ system” because if the indicated polymer is the main component, secondary components may be blended according to the purpose or introduced by graph-polymerization. This is because it may be any of random or block copolymers.
- the modified cross-section hollow fiber membrane used in the present invention is made of the above-mentioned thermoplastic resin, and more preferably is made of a synthetic polymer having a contact angle of 70 degrees or less.
- the contact angle of the synthetic polymer refers to a uniform film made from a synthetic polymer or a product prepared by uniformly applying a synthetic polymer to a horizontal carrier such as a glass plate and drying it. This is the angle between the tangent line drawn to the liquid and the plane containing the liquid at the three-phase contact point of the droplet, synthetic polymer surface, and gas phase.
- the hollow fiber membrane is made of such a synthetic polymer, in particular, since cell adhesion to the inner surface can be suppressed to some extent, and a decrease in the material permeability of the membrane due to cell adhesion is reduced.
- the wettability to the liquid to be treated such as blood, plasma, and physiological solution is good, and it is also preferable in terms of material exchange through the membrane.
- Synthetic polymers satisfying such a contact angle of 70 degrees or less include the thermoplastics described above.
- those obtained by applying the above-described thermoplastic resin to a film made of any material can also be used.
- At least the inner surface of these modified cross-section hollow fiber membranes may contain a hydrophilic polymer for the purpose of controlling affinity with cells.
- hydrophilic polymers include hydrophilic synthetic polymers such as polyethylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone, ethylene vinyl alcohol copolymer, polyethyleneimine, polyallylamine, cellulose, chitosan, agarose, dextran, dextran.
- hydrophilic polysaccharides such as sulfuric acid, but are not limited to these, and any can be used as long as it can control the engraftment of cells.
- an ethylene vinyl alcohol copolymer is particularly preferable.
- the ethylene vinyl alcohol copolymer has, for example, a high rate of hepatocyte organoid formation in the initial stage.
- the cell adhesion is low and the material permeability of the membrane is not impaired.
- hydrophilic polymers may be introduced to at least the inner surface of the modified cross-section hollow fiber membrane by any method other than coating, such as blending, graft polymerization, and copolymerization. Of course, it may be introduced into the entire film.
- the hollow fiber membrane-type cell-containing device of the present invention is a cell aggregate (organoide) obtained by filling cells into the hollow interior of the modified cross-section hollow fiber membrane and aggregating them.
- the cell aggregate (organoide) referred to in the present invention refers to a cell tissue body in which cells are accumulated and approximates an organ (organ) having a function inherent to the cell tissue.
- a tissue body in which hepatocytes obtained in the present invention are accumulated is a cell aggregate (organoide) because it has liver functions such as an ammonia removal effect and an albumin secretion effect inherent in the liver tissue.
- the cell aggregate (organoide) referred to in the present invention is obtained by utilizing a mechanical method such as centrifugal force or pressure as defined in Japanese Patent Application Laid-Open No. 20 0 2- 1 8 2 6 7 7.
- Filling cells ⁇ Not limited to cell aggregates formed by densification.
- hepatocytes are proliferated in the hollow fiber lumen by filling the hollow fiber lumen with hepatocytes and culturing with a perfusate.
- the cells used in the present invention are animal tissue-derived cells, and depending on the collection site, liver-derived cells (including at least one of hepatocytes, endothelial cells, Kupffer cells, fibroblasts), spleen-derived cells, In addition to organ-derived cells such as cardiomyocytes and kidney-derived cells, there are also tissue cells such as skin cells, epidermal keratinocytes, fibroblasts, vascular endothelial cells, vascular wall cells, nerve cells, and chondrocytes. You can use these in combination. In addition to these mature cells, stem cells and progenitor cells may be used depending on the differentiation stage. Furthermore, genetically modified cells can be used for these normal cells. Examples of genetically modified cells include cells that have been immortalized by introducing an immortalizing gene such as Tert, Bmi 1, SV40 LargeT, or Bcl 2 by genetic manipulation.
- an immortalizing gene such as Tert, Bmi 1, SV40 LargeT, or Bcl 2 by genetic manipulation.
- hepatocytes are most preferable as the cells used in the deformed hollow fiber membrane type cell-containing device of the present invention.
- the liver is the largest organ, and it synthesizes and stores substances necessary for the body including proteins and carbohydrates, or metabolic detoxification of ammonia and drugs, and releases bile acids as an exocrine organ. It has a wide variety of functions, such as being involved in fat digestion and vitamin absorption. Therefore, a device using hepatocytes is very useful in terms of function despite its small size.
- the cell source of the present invention is normal hepatocytes derived from mice, rats, guinea pigs, rabbits, dogs, pigs, baboons, humans, etc., but is not limited thereto. Also, Established established hepatocytes are also targeted.
- isolated hepatocytes can be obtained by using a general enzyme digestion method in which the liver is treated with an enzyme solution such as a collagenase solution.
- the density of the cells filled in the modified cross-section hollow fiber membrane is preferably 1 ⁇ 10 7 cells / cm 3 or more. This is because if the cell density is higher than this, it can be made compact when used as an embedded or circulatory type hybrid artificial organ.
- the cell density is greater than 5 X 10 7 cel Is / cm 3 and less than or equal to 2 X 10 8 cel Is / cm 3 , 8 x 10 7 ce II s / cm 3 or more is preferable, and 9 x 10 7 cel Is / cm 3 or more is more preferable.
- the cell aggregate (organoide) of the present invention requires cells to be laminated in two or more layers in an arbitrary direction, and if it has a thickness of two or more layers, the cell aggregate (organoide) The function of can be demonstrated.
- a stack of two or more cells in an arbitrary direction means that two or more cells are laminated even if a cell aggregate (organoide) is cut in any radial cross section.
- the distance from any point of the cell assembly to the nearest inner wall of the hollow fiber membrane is less than 75 / m” means that it is hollow from any point of the cell assembly (organoide) formed in the hollow part. This means that the distance to the inner wall of the yarn cannot be more than 75 / m.
- the thickness of the cell assembly (organo node) in the present invention is two or more layers, and the distance from an arbitrary point of the cell assembly (organ node) formed in the hollow portion to the inner wall of the nearest hollow fiber Must be less than 75 m.
- the thickness refers to the thickness from the surface layer to the surface layer of the cell assembly (organoide).
- the thickness (length) of the cell assembly (organoide) formed in the deformed hollow fiber membrane in the fiber axis direction. ) Can be set arbitrarily.
- Another example is a modified hollow fiber membrane. In the case of a flat shape, the thickness in the major axis direction can be arbitrarily set as long as the thickness in the minor axis direction satisfies the above.
- the cell density of the cell aggregate (organoide) is high, the voids are reduced, so that the thickness cannot be increased too much for the supply of oxygen, while the cell density is relatively small even within the range of the present invention. Sometimes thicker is better. Therefore, in the cell aggregate (organoide) of the present invention, it is more preferable that the cell density and the thickness have an inverse correlation.
- each cell is in three-dimensional contact with each other except the surface.
- hepatocytes in the living liver express information by exchanging information through various cell connections between adjacent cells.
- a hepatocyte is filled with a high density by applying a physical force such as centrifugal force or hydrostatic pressure, and a tissue body with a high cell density is achieved by dramatically improving the contact frequency between cells.
- a physical force such as centrifugal force or hydrostatic pressure
- the cell aggregate (organoide) of the present invention preferably has a skin layer on the surface of the aggregate.
- the cells on the surface of the cell aggregate (organoide) become flattened and the cell aggregate ( Organoid)
- the surface layer becomes smooth and the skin layer appears. This skin layer is thought to be due to the cell state and cell secretions of the surface of the cell aggregate (organoide).
- At least one of the modified cross-section hollow fiber membranes of the present invention is accommodated in a container having an inlet and outlet for a culture solution or a liquid to be treated and an inlet for cells, and the hollow interior communicates with the inlet for cells.
- a module obtained by potting so as to be isolated from the hollow exterior forming the flow path of the liquid to be treated the hollow cells of the hollow fiber membrane are filled with target cells to form cell aggregates (organoide)
- FIGS. 12 and 13 are schematic diagrams of hybrid artificial organs incorporating the modified cross-section hollow fiber membrane according to the present invention.
- a container 2 having an inlet and an outlet (5 and 6) for a culture solution or a liquid to be treated is filled with at least one modified cross-section hollow fiber membrane 1. Both ends of the modified cross-section hollow fiber are potted and fixed so that the hollow interior communicates with the cell inlet at the sealing portion 3 and is isolated from the hollow exterior forming the flow path of the liquid to be treated. .
- any container material and shape generally used in a hollow fiber membrane blood purifier can be used.
- a container material a material having high strength, high transparency, and excellent safety, such as a polystrength boronate resin and a polystyrene resin, is suitable.
- inexpensive polyolefin resins and various copolymer resins may be used, and there is no particular limitation.
- the container shape it suffices that the body portion is cylindrical and the flow port for the liquid to be treated is provided in the vicinity of both ends, and at least one modified cross-section hollow fiber membrane type cell-containing device of the present invention is contained therein. Contains more than one book.
- a hollow fiber membrane in a container is potted at both ends, and the inside and outside of the membrane are isolated, such as a hollow fiber membrane blood purifier, and an example of an endotoxin force filter
- both ends are potted, but one end is blinded
- the hollow fiber membrane is U-shaped in the container as an example of a household hollow fiber membrane water purifier. It can take any form, such as one that is loaded into a mold and one end of which is potted, and there is no particular limitation.
- the module is provided with at least one cell inlet 4 for introducing cells in addition to the inlet and outlet (5 and 6) of the culture medium or the liquid to be treated. Is introduced into the hollow portion of each hollow fiber membrane through the open end of the hollow fiber membrane of the sealing portion 3.
- the sealing part 3 at the other end is sealed in advance with the hollow fiber open end or after cell introduction.
- the cell is injected into the hollow part by sealing the cell injection side sealing part 3 by a process such as sealing the cell inlet 4. It is fixed.
- This is the hybrid artificial organ referred to in the present invention. Of cells fixed in the hollow The situation is schematically shown in Fig. 13.
- the space inside the container 2 formed by the outside of the hollow fiber membrane and the sealing portion is filled in the hollow fiber of the irregular cross section, and oxygen for the cells forming the cell aggregate (organoide)
- the culture solution for supplying nutrients and removing metabolic waste products is perfused through the culture solution inlet 5 and the culture solution outlet 6.
- blood, plasma, diluted solutions thereof, and blood products may be perfused into this space as the liquid to be treated.
- the hollow fiber membrane incorporated therein is a hollow fiber membrane with a modified cross section, so that the liquid to be treated flows easily through the gaps between the membranes, and material exchange such as detoxification and removal It can be suitably used as a hybrid artificial organ that is highly efficient and can maintain its function for a long period of time.
- a hollow fiber membrane available on the market can be obtained by appropriately modifying it, there is an advantage that a cell aggregate (organoide) filled in a membrane permeable to any material and substance can be used.
- the modified cross-section hollow fiber membrane of the present invention can be formed by any spinning method such as a known wet method, dry-wet method, and melt method, but a film forming method suitable for the membrane material to be used is appropriately selected. That's fine.
- a method for obtaining a modified cross-section hollow fiber membrane there are a method of forming a modified cross-section at the same time as film formation, and a method of deforming the hollow fiber membrane after film formation by applying a mechanical treatment.
- the former it is only necessary to discharge and solidify a membrane-forming stock solution from an annular double nozzle having an irregular cross section, and by using a nozzle having a desired cross-sectional shape, the hollow fiber membrane can have an irregular cross section of any shape. Is preferable.
- a deformed external force may be applied to the formed hollow fiber membrane from a direction substantially perpendicular to the fiber axis. For example, as shown in FIG.
- the hollow fiber membrane can be cut into an appropriate length and deformed by a press machine having a specific shape. Or, a slot with a specific width and shape that sandwiches the hollow fiber membrane. It is preferable to use a roller, since it can be continuously deformed even during or after the spinning process. Since such deformation processing after film formation can be used including all commercially available hollow fiber membranes, even if the inner diameter is so large as to be unsuitable for organoids, it can be obtained by flattening or the like. It can be transformed into a size, which is very preferable in that it can take advantage of membrane material and material permeability. In any case, it is more preferable to apply a heat set by applying a temperature that does not denature the membrane material when applying the deformation external force.
- a step of injecting the cell suspension into the hollow of the modified cross-section hollow fiber membrane is necessary.
- at least one end of the hollow fiber membrane is resin potted, and the open end of the hollow fiber membrane is not cured after curing. The resin is cut to form.
- a cell suspension injection jig or nozzle or the like may be attached to the open end, but there is no particular limitation on the sealing means or injection jig.
- the obtained modified cross-section hollow fiber membrane is used as a culture solution or a liquid to be treated. Is loaded into a cylindrical container having an inlet and an outlet, and at least one end thereof is potted.
- the potting form is not particularly limited, and may be potting at both ends, or may be one-end potting in which a hollow fiber membrane is loaded in a U shape. It is only necessary to be isolated so that no pass occurs.
- the end of the resin is cut to create an open end of the modified cross-section hollow fiber membrane, and a header cap having a cell inlet may be attached thereto.
- a series of molding methods so far may be in accordance with known hollow fiber membrane blood purifiers and water purifiers, and there is no particular limitation.
- the opening end or the header nozzle opposite to the cell injection port is sealed so that the injected cells do not flow away.
- the method includes a step of increasing the density by injecting cells into the hollow fiber and applying a physical force such as centrifugal force or hydrostatic pressure.
- a centrifugal loading method cell aggregates (organoides) can be obtained by densifying cells and culturing them for a predetermined time.
- a cell aggregate (organoide) can be obtained by applying a hydrostatic pressure for a predetermined time and culturing.
- hepatocytes are proliferated in the hollow fiber lumen to produce an intercellular matrix, and further, adhesion between cells, or cell-cell matrix Cell aggregates can also be obtained by advancing adhesion.
- the cells are made into a cell suspension and injected into the hollow fiber so as not to damage the cells.
- concentration of the cell suspension is preferably 2 X 10 7 ce l I s / ml or less in order to increase the density without damaging the cells, more preferably 0.1 to 1 x 10 7 ce II s / ml. preferable.
- hydrostatic pressure When applying hydrostatic pressure, erect a hollow fiber into which cells have been injected, and apply a hydrostatic pressure of 5 to 25 kPa for 4 to 120 hours. Most preferably, a constant hydrostatic pressure of 10 kPa is applied for 24 hours.
- the cell-containing device of the present invention can be obtained by culturing the cells to form a cell aggregate (organoide).
- Culture media include serum-free media supplemented with hormones and inorganic salts in basic media such as William E medium (WE) and Dulbecco's modified Eagle medium (DMEM), or WE or DMEM
- basic media such as William E medium (WE) and Dulbecco's modified Eagle medium (DMEM), or WE or DMEM
- WE William E medium
- DMEM Dulbecco's modified Eagle medium
- WE DMEM
- a serum-added medium obtained by adding serum to a basal medium is used.
- a cell-containing device in which cells are filled and fixed in a modified cross-section hollow fiber membrane can be effectively used as a hybrid artificial organ set in a container and modularized.
- a hollow fiber membrane part is collected from a deformed cross-section hollow fiber membrane or a hybrid artificial organ after forming a cell aggregate (organoide), and both ends thereof are sealed by an arbitrary method so that cells do not leak. Even those that have stopped can be suitably used.
- the sealing shape of the hollow fiber membrane is not particularly limited as long as the filled cells do not leak from the opening of the membrane.
- the hollow fiber membrane is made of a known biodegradable polymer because it can be used as an embedded type.
- a modified cross-section hollow fiber membrane type cell-containing device having such a sealing structure and comprising a hollow fiber membrane and a cell can also be suitably used as a device for an artificial organ capable of maintaining the function for a long period of time.
- the hollow fiber membranes available on the market can be obtained by appropriately deforming them, there is an advantage that cell aggregates (organo- ides) filled in membranes of any material and substance permeability can be used.
- hepatocytes used for the formation of cell aggregates (organoides) in the present invention and measurement of functional activity of the obtained hepatocyte cell aggregates (organoides) were performed as follows.
- hepatocytes In order to prepare primary rat hepatocytes, 150 ml of an O mgZml collagenase (Wako Pure Chemical Industries) solution was prepared. A force neulet was introduced into the portal vein (blood vessel entering the liver) of a 7-week-old male Wistar rat (body weight 250 g), and blood removal was allowed to flow for 5 minutes at SOml lmin and then heated to 37 ° C. The collagenase solution thus prepared was allowed to flow at 15 ml / min for 10 minutes. Place the liver treated with collagenase in the medium and disperse the hepatocytes using a scalpel and a pipette. Let The obtained hepatocyte suspension was washed 3 times to remove cells other than hepatocytes (purity of 95% or more). A final hepatocyte suspension density of 2.0 ⁇ 10 6 cel Is / ml was prepared and used for culture experiments.
- O mgZml collagenase (Wako Pure Chemical Industries) solution was prepared.
- Ammonia was added to the culture medium to a concentration of 1 mM, the amount of decrease in ammonia concentration over time was measured, and the ammonia removal rate (mo I / 10 6 i country eel eel Is / day) was calculated. did.
- Albumin secreted into the culture medium was quantified by enzyme-labeled immunoassay and converted to the albumin secretion rate per initial immobilized unit cell number (ju gZl 0 6 i fraction obilized eel Is / day).
- PE / EVAL hollow fiber Polyethylene hollow fiber membrane coated with ethylene vinyl alcohol copolymer
- PP hollow fiber polypropylene hollow fiber membrane
- an irregular cross-section hollow fiber membrane was created using an inner diameter of 330 jum and a film thickness of 50 jum. That is, by sandwiching the hollow fiber membrane and a stainless steel spacer with a thickness of 100 mm between two glass plates and leaving the central portion of the glass plate fixed with a clip for 6 hours at 120 ° C
- a deformed cross-section hollow fiber membrane was created by heat setting.
- the produced modified cross-section hollow fiber membranes are indicated as PE / EVAL hollow fiber-press100 and PP hollow fiber-presslOO, respectively.
- the obtained modified cross-section hollow fiber membrane was embedded in liquid silicon, and then the cross-sectional shape was observed by preparing a thin section.
- the surface structure of the obtained modified cross-section hollow fiber membrane was observed using a scanning electron microscope (SEM). The observation results are shown in Figs.
- hepatocyte aggregates organoides
- a bundle consisting of 9 PE / EVAL-press100 hollow fibers 5 cm in length and 6 PP-press100 hollow fibers 5 cm in length
- Each of the bundles was formed with a modified cross-section hollow fiber membrane bundle.
- a cell injection port was attached to one end of each bundle, and the other end was completely sealed.
- the cell suspension of 2.0x10 6 cel IsZml was injected from the cell injection port using a syringe, and at the same time, the cells were filled into the hollow fiber membrane having an irregular cross section while removing the culture solution from the hollow fiber membrane hole by filtration.
- centrifugation was performed at 60XG for 90 seconds to perform high-density packing, thereby inducing the formation of hepatocyte aggregates (organoides).
- hepatocytes filled in the hollow fiber bundle were immobilized with a 10% neutral buffered formalin solution in each period of culture. Then, after embedding in paraffin and preparing thin sections, the distribution of live and dead cells was observed by staining with hematoxylin and eosin. Also, during each culture period, hepatocytes were crushed with a hollow fiber bundle using a polytron homogenizer, and the leaked nuclei were stained with a crystal violet, and the number of nuclei was counted to change the number of cells. It was measured. The culture state is shown in FIG. 6, and the change in cell number is shown in FIG.
- ammonia was added to the culture medium to a concentration of 1 mM, and its activity was evaluated by measuring the amount of ammonia concentration with time. Moreover, the activity was evaluated by quantifying albumin secreted into the culture medium. The results are shown in FIGS.
- PE / EVAL hollow fiber control Polyethylene hollow fiber membrane coated with ethylene vinyl alcohol (hereinafter referred to as PE / EVAL hollow fiber control; inner diameter 330 / im, film thickness 50 im), and polypropylene hollow fiber membrane (hereinafter referred to as PP hollow fiber control). With an inner diameter of 330 m and a film thickness of 50 m.) A hepatocyte aggregate (organoide) was formed in the same manner as in Example 1 except that the profile processing was not performed, and the function of the hepatocytes was evaluated.
- PE / EVAL hollow fiber control Polyethylene hollow fiber membrane coated with ethylene vinyl alcohol
- PP hollow fiber control polypropylene hollow fiber membrane
- the deformed hollow fiber membrane has a 200m thick stainless steel spacer.
- a stainless steel spacer having a thickness of 100 m By using a stainless steel spacer having a thickness of 100 m, a deformed hollow fiber membrane having a minor axis of about 50 to 75 m at the inner periphery of the membrane was obtained.
- cell aggregates organoide
- cell aggregates (organoides) in which hepatocytes were in close contact with each other were formed.
- the changes in ammonia removal rate and albumin secretion rate per initial number of immobilized cells are shown in FIGS. 8 and 9, and the modified cross-section hollow fiber membrane bundle of the present invention is used. In this case, no necrosis layer was formed inside the hepatocyte aggregate (organoide), and therefore, good functional expression was maintained.
- PE / EVAL hollow fiber polyethylene hollow alcohol membrane coated with ethylene vinyl alcohol copolymer on the surface of the hollow fiber membrane to make it hydrophilic
- CTA hollow fiber a hollow fiber membrane made of cellulose-reedate having a more hydrophobic surface than a PE / EVAL hollow fiber
- a cell introduction port was connected to one end of the bundle, and the other end was completely sealed. Filling and culturing the cells inside the hollow fiber membrane was carried out in the same manner as in Example 1 except that 0.5 ml of a cell suspension of 4.0 ⁇ 10 e cEL I sZml was injected.
- the hollow fiber bundle was left in a 10% neutral buffered formalin solution for 24 hours to immobilize hepatocytes filled in the hollow fiber. After the fixation treatment, the hollow fiber was clarified and the cell morphology of the hepatocytes was observed. The hollow fiber filled with hepatocytes was cleaved in the long axis direction with a scalpel to expose the inner wall surface of the hollow fiber and observed with a low vacuum scanning electron microscope.
- Figure 1 shows the morphology of hepatocytes in PEZEVAL hollow fiber and CTA hollow fiber after 1 hour of culture. 0.
- hepatocytes were packed in the CTA hollow fiber at a high density, but no cell aggregate (organoide) was formed yet.
- cell aggregates (organoides) were already formed inside the PEZEVAL hollow fiber that had been subjected to hydrophilization, and a difference in the rate of cell aggregate (organoide) formation was observed.
- FIG. 11 the state of the inner wall surface of PEZEVAL hollow fiber and CTA hollow fiber on the first day of culture is shown in Fig. 11.
- cylindrical cell aggregates organonodes
- numerous hepatocytes were observed to adhere to the inner wall of the hollow fiber.
- PE / EVAL hollow fibers showed no cell attachment to the inner wall of the hollow fibers, and all hepatocytes formed columnar cell aggregates (organoids).
- the hydrophilic treatment on the surface of the hollow fiber membrane suppresses the adhesion of cells to the hollow fiber membrane, and is effective for early formation of cell aggregates (organoide). This is effective in that it can avoid the deterioration of the property.
- Example 1 Obtained in Example 1 inside a polycarbonate housing container with a volume of 1.79 cm 3 .
- a schematic diagram of the fabricated module is shown in Fig. 12.
- the modified cross-section hollow fiber membrane 1 is fixed in the container 2 using a urethane potting agent, and the sealing part 3 that completely blocks the spaces on the cell introduction side and the medium perfusion side in the container 2 Formed.
- a header cap with a cell injection port 4 installed in the container 2 was attached. In order to perform cell seeding, the sealing part 3 and the cell injection port 4 at one end of the module were completely enclosed in advance.
- the primary rat hepatocytes isolated by enzyme treatment were adjusted to a suspension of 4 x 10 6 cells / ml, and then 13 ml of the cell suspension was removed from the cell injection port 4 with a modified cross-section hollow fiber membrane. After injection into the hollow part, cells were completely filled into the hollow part using centrifugation conditions of 60 ⁇ g and 90 seconds. After filling the cells, the injected cell injection port 4 was sealed, and the culture solution was perfused from the culture solution inlet 5 and the culture solution outlet 6 for culturing.
- a cell aggregate (organoide) in which a necrotic layer does not occur can be obtained as a hybrid artificial organ incorporating a device having a modified cross-section hollow fiber membrane cell.
- such modules were suggested to be effective for use as substance production devices and cell culture devices.
- the cells filled in the hollow fiber membrane function efficiently without waste by using the hollow fiber membrane type cell-containing device. It was suggested that it can be suitably used as a hybrid artificial organ.
- the hollow fiber membrane-type cell-containing device of the present invention is not limited to an implantable or hybrid-type artificial organ, but a substance production apparatus (bioreactor) using cells or a cell culture device (such as a stem cell amplifier) for growing rare cells.
- a substance production apparatus biological reactor
- a cell culture device such as a stem cell amplifier
- it can be suitably used for various applications.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- External Artificial Organs (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004532757A JP4187167B2 (ja) | 2002-08-28 | 2003-08-28 | 異形断面中空糸膜型細胞含有デバイス |
US10/525,707 US7695958B2 (en) | 2002-08-28 | 2003-08-28 | Cell-filled hollow fiber membranes having modified cross-section |
AU2003261798A AU2003261798A1 (en) | 2002-08-28 | 2003-08-28 | Cell-filled device of modified cross-section hollow fiber membrane type |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002249594 | 2002-08-28 | ||
JP2002-249594 | 2002-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004020614A1 true WO2004020614A1 (ja) | 2004-03-11 |
Family
ID=31972588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010952 WO2004020614A1 (ja) | 2002-08-28 | 2003-08-28 | 異形断面中空糸膜型細胞含有デバイス |
Country Status (4)
Country | Link |
---|---|
US (1) | US7695958B2 (ja) |
JP (1) | JP4187167B2 (ja) |
AU (1) | AU2003261798A1 (ja) |
WO (1) | WO2004020614A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011092065A (ja) * | 2009-10-28 | 2011-05-12 | Genomix Co Ltd | 埋め込み式生体内物質採取デバイス |
JP2017077473A (ja) * | 2015-10-21 | 2017-04-27 | 国立大学法人 東京大学 | マイクロチューブ、マイクロチューブの製造方法、及びマイクロチューブの製造装置 |
JP2018050498A (ja) * | 2016-09-27 | 2018-04-05 | ユニチカ株式会社 | 細胞培養用中空糸膜及び細胞培養方法 |
JP2022500058A (ja) * | 2018-09-27 | 2022-01-04 | チルドレンズ ホスピタル メディカル センター | 肝臓オルガノイドを含む肝臓サポートシステムとその製造および使用方法 |
JP7523732B2 (ja) | 2020-02-27 | 2024-07-29 | ひとみ 森野 | 細胞採取具 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100179659A1 (en) * | 2006-09-27 | 2010-07-15 | Wan-Ju Li | Cell-nanofiber composite and cell-nanofiber-hydrogel composite amalgam based engineered intervertebral disc |
JP5722885B2 (ja) | 2009-06-18 | 2015-05-27 | セレクティス アーベー | ヒト多能性幹(hPS)細胞の成長および分化のための3D培養システム |
US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
CN102166380B (zh) * | 2011-03-17 | 2013-03-27 | 南方医科大学南方医院 | 基于双层硝酸纤维素膜灌流式的生物人工肝反应器 |
WO2015183920A2 (en) | 2014-05-28 | 2015-12-03 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
AU2015331848B2 (en) | 2014-10-17 | 2022-03-03 | Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
CN116790476A (zh) | 2016-05-05 | 2023-09-22 | 儿童医院医疗中心 | 用于体外制造胃底组织的方法和与其相关的组合物 |
KR20230110839A (ko) | 2016-12-05 | 2023-07-25 | 칠드런즈 호스피탈 메디칼 센터 | 결장 유사장기 및 이를 제조 및 사용하는 방법 |
CN111187802B (zh) * | 2020-01-15 | 2023-06-06 | 杭州师范大学 | 基于中空纤维膜的细胞活性小分子连续监测装置和方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58142042U (ja) * | 1982-03-18 | 1983-09-24 | 旭メデイカル株式会社 | 非真円形断面中空糸 |
JPS62171678A (ja) * | 1986-01-23 | 1987-07-28 | Teijin Ltd | 細胞培養方法及び培養器 |
EP1078982A2 (en) * | 1999-08-25 | 2001-02-28 | Toyo Boseki Kabushiki Kaisha | Cell culture module having sinusoid-like structure |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58142042A (ja) | 1982-02-15 | 1983-08-23 | Toshiba Ceramics Co Ltd | ブレ−キライニング材 |
US5100775A (en) * | 1988-03-16 | 1992-03-31 | Smyczek Peter J | Method for conducting nucleic acid hybridization in chamber with precise fluid delivery |
JPH10108673A (ja) * | 1996-10-04 | 1998-04-28 | Asahi Medical Co Ltd | 中空糸型培養器を用いた動物細胞の培養方法 |
US6242248B1 (en) * | 2000-02-08 | 2001-06-05 | Cedars-Sinai Medical Center | Bioreactor and related method |
US6802820B1 (en) * | 2000-04-13 | 2004-10-12 | Transvivo, Inc. | Specialized hollow fiber membranes for in-vivo plasmapheresis and ultrafiltration |
-
2003
- 2003-08-28 WO PCT/JP2003/010952 patent/WO2004020614A1/ja active Application Filing
- 2003-08-28 AU AU2003261798A patent/AU2003261798A1/en not_active Abandoned
- 2003-08-28 US US10/525,707 patent/US7695958B2/en active Active
- 2003-08-28 JP JP2004532757A patent/JP4187167B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58142042U (ja) * | 1982-03-18 | 1983-09-24 | 旭メデイカル株式会社 | 非真円形断面中空糸 |
JPS62171678A (ja) * | 1986-01-23 | 1987-07-28 | Teijin Ltd | 細胞培養方法及び培養器 |
EP1078982A2 (en) * | 1999-08-25 | 2001-02-28 | Toyo Boseki Kabushiki Kaisha | Cell culture module having sinusoid-like structure |
Non-Patent Citations (1)
Title |
---|
KAZUHISA NAGATA ET AL.: "Ikei danmen chukushi o riyo shita kansaibo soshikitai (organoid) baiyoho no kaihatsu", THE SOCIETY OF CHEMICAL ENGINEERS, JAPAN DAI 68 NENKAI KENKYU HAPPYO KOEN YOSHISHU (L316), February 2003 (2003-02-01), pages 452, XP002975694 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011092065A (ja) * | 2009-10-28 | 2011-05-12 | Genomix Co Ltd | 埋め込み式生体内物質採取デバイス |
JP2017077473A (ja) * | 2015-10-21 | 2017-04-27 | 国立大学法人 東京大学 | マイクロチューブ、マイクロチューブの製造方法、及びマイクロチューブの製造装置 |
JP2018050498A (ja) * | 2016-09-27 | 2018-04-05 | ユニチカ株式会社 | 細胞培養用中空糸膜及び細胞培養方法 |
JP2022500058A (ja) * | 2018-09-27 | 2022-01-04 | チルドレンズ ホスピタル メディカル センター | 肝臓オルガノイドを含む肝臓サポートシステムとその製造および使用方法 |
JP7523732B2 (ja) | 2020-02-27 | 2024-07-29 | ひとみ 森野 | 細胞採取具 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004020614A1 (ja) | 2005-12-15 |
AU2003261798A1 (en) | 2004-03-19 |
JP4187167B2 (ja) | 2008-11-26 |
US20060110369A1 (en) | 2006-05-25 |
US7695958B2 (en) | 2010-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2244659C (en) | Biological reactor for the cultivation of cells | |
JP5524824B2 (ja) | 改良されたバイオリアクタ表面 | |
WO2004020614A1 (ja) | 異形断面中空糸膜型細胞含有デバイス | |
Jain et al. | Biomaterials for liver tissue engineering | |
EP2329010B1 (en) | Device for renal cell expansion | |
US20110263020A1 (en) | Membrane for cell expansion | |
WO2016021498A1 (ja) | 繊維状タンパク質材料の作製方法、および細胞培養方法 | |
JPS63196286A (ja) | 細胞培養用基材 | |
Wells et al. | Microencapsulation of viable hepatocytes in HEMA-MMA microcapsules: a preliminary study | |
Chen et al. | Loofa sponge as a scaffold for the culture of human hepatocyte cell line | |
JP6241890B2 (ja) | 血管組織およびその作製方法 | |
EP1980613B1 (en) | Method of maintaining the function of liver tissue cells over long time | |
Fukuda et al. | Hepatocyte organoid culture in elliptic hollow fibers to develop a hybrid artificial liver | |
JPS63196281A (ja) | 細胞培養用基材 | |
JPH06277050A (ja) | 動物細胞の固定化物および培養方法 | |
JPH04237492A (ja) | 細胞培養用成形物 | |
JPH0315382A (ja) | 細胞培養用基材、細胞培養用基材ユニット、バイオリアクターおよび体外循環式治療器 | |
JPS62130678A (ja) | 細胞培養用中空糸膜 | |
Kreuels et al. | 3D-printed scaffolds with perfusable channels for low-cost large construct 3D cell culture | |
JPH0833474A (ja) | 付着性動物細胞の培養基体 | |
JPH0833475A (ja) | 付着性動物細胞の培養基体 | |
Yanagi et al. | A high-density culture of hepatocytes using porous substrate for use as a bioartificial liver | |
JPS63196277A (ja) | 細胞培養用基材 | |
US20210379799A1 (en) | Device for manufacturing large amount of polymeric micro-scaffolds | |
JPH03292885A (ja) | 細胞培養方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004532757 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006110369 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10525707 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10525707 Country of ref document: US |